Clinical Trials

100 enrolled

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

NCT05821556 2026-04-14

Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients

240 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT02688712 2026-04-13

ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer

50 enrolled

Rectal Neoplasms

NCT04768426 2026-04-13

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT06417476 2026-04-13

Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer

66 enrolled

Rectal Neoplasms

NCT07340541 2026-04-13

EVOLVE-BDT

700 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07521605 2026-04-13

Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer

44 enrolled

Rectal Cancer Patients

NCT03764553 2026-04-07

LyRICX

320 enrolled

Esophageal Neoplasms

NCT07515625 2026-04-07

Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma

46 enrolled

Stomach Neoplasms

NCT07112053 2026-04-06

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8

NCT04245865 2026-04-03

Toco-CoR

83 enrolled

Colorectal Neoplasms

NCT04309578 2026-04-03

A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC

Phase 2 Completed

28 enrolled

Tumor-Agnostic

Adenocarcinoma

NCT06281405 2026-04-03

TORCH-iTNT

192 enrolled

Locally Advanced Rectal Cancer

NCT07509424 2026-04-03

Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance

29 enrolled

Rectal Neoplasms

NCT07503639 2026-03-31

Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer

134 enrolled

Locally Advanced Colorectal Cancer

NCT07281768 2026-03-20

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

66 enrolled

Adenocarcinoma, Carcinoma, Rectal Neoplasms, Colorectal Neoplasms

NCT07203729 2026-03-16

The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis

184 enrolled

Breast Neoplasms

NCT07468630 2026-03-12

TRIUNITE-08

106 enrolled

Colonic Neoplasms

NCT06647680 2026-03-06

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

35 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT05731726 2026-03-05

Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer

50 enrolled

Rectal Neoplasms

NCT07303283 2026-03-05

Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma

218 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06016387 2026-02-23

Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study

30 enrolled

Breast Neoplasms, Meningeal Neoplasms

NCT07417241 2026-02-18

SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study

100 enrolled

Breast Neoplasms

NCT06291064 2026-02-17

TARMAC

85 enrolled

Triple Negative Breast Neoplasms

NCT07407465 2026-02-17

CHIMERA

42 enrolled

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT07395063 2026-02-09

A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.

68 enrolled

Colorectal Neoplasms

NCT07392320 2026-02-06

A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma

142 enrolled

Nasopharangeal Cancer

NCT05062889 2026-02-03

ERASE-CRC

Phase 2 Suspended

477 enrolled

Colonic Neoplasms

NCT07383285 2026-02-03

CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer

106 enrolled

Rectal Neoplasms Malignant

NCT07381777 2026-02-02

IMMUNOSTAR

270 enrolled

Locally Advanced Rectal Cancer (LARC)

NCT06123338 2026-01-29

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

49 enrolled

Esophageal Neoplasms

NCT01494662 2026-01-23

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Phase 2 Completed

140 enrolled 32 charts

Breast Neoplasms

NCT04165772 2026-01-23

Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

200 enrolled

Rectal Neoplasms

NCT05807880 2026-01-23

ALTER-HN005

59 enrolled

Head & Neck

Nasopharyngeal Neoplasms

NCT07222215 2026-01-22

CAPELA

297 enrolled

Breast Neoplasms

NCT03257163 2026-01-20

Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer

Stomach Neoplasms

NCT05693766 2026-01-20

INSIGHT

64 enrolled

Breast Neoplasms

NCT04539808 2026-01-14

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

42 enrolled 13 charts

Pancreatic Adenocarcinoma

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Breast Neoplasms

NCT07229846 2026-01-08

A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation

30 enrolled

Colorectal Neoplasms

NCT06105684 2026-01-07

Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer

Breast Neoplasms

NCT07068763 2026-01-06

mRCAT-E

52 enrolled

Rectal Neoplasms

NCT03921684 2026-01-05

Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients

29 enrolled

Rectal Neoplasms

NCT06332079 2026-01-05

HAITI

Phase 2 Terminated

4 enrolled

Colorectal Cancer Metastatic

NCT07281157 2025-12-30

Irinotecan Liposome Plus Capecitabine and Enronsubemab Combined With Short-course Radiotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cancer

30 enrolled

Advanced Colorectal Cancer

NCT06540326 2025-12-22

Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab

100 enrolled

Colorectal Cancer Metastatic

NCT07296666 2025-12-22

Adjuvant Chemotherapy for BTC Based on 3D-PTA

98 enrolled

Cholangiocarcinoma

NCT06085742 2025-12-19

BRE-08

25 enrolled

Breast Neoplasms

NCT05472948 2025-12-17

Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma

36 enrolled

Appendiceal Neoplasms, Neoplasm Metastasis

NCT04965064 2025-12-15

Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling